Bone Scintigraphy in Pulmonary Alveolar Microlithiasis

Mehul Shah and J.M. Joshi

Department of Pulmonary Medicine, T.N. Medical College and B.Y.L. Nair Hospital, Mumbai, India

[Indian J Chest Dis Allied Sci 2011;53:221-223]

CLINICAL SUMMARY

A 33-year-old woman, recently diagnosed to have cholelithiasis and advised cholecystectomy, was referred for evaluation of chest radiograph abnormality detected during pre-operative evaluation. She had no present or past history of any major respiratory illness. Physical examination revealed bilateral basal crackles on auscultation.

INVESTIGATION

Haemogram parameters and serum biochemistry, including calcium, phosphorous and alkaline phosphatase levels were within normal limits. The chest radiograph (Figure 1) showed bilateral middle-zone and lower-zone dense reticulonodular opacities. High resolution computed tomography (HRCT) of the chest (Figures 2 and 3) showed bilateral intra-lobular interstitial and septal thickening with a perivascular distribution pattern and dense calcification along with the presence of small subpleural cysts on both sides.
Technetium-99m methylene diphosphonate (Tc-99m MDP) whole body bone scintigraphy (Figure 4) showed diffusely increased radiotracer uptake in both the lungs. Whole body 18-fluorodeoxyglucose positron emission tomography (FDG-PET) did not show any significant uptake in the lungs. Microscopic examination of sputum and bronchial washings did not show presence of “calcospherites”.

The hallmark of this disorder is a clinico-radiological dissociation, i.e. there is paucity of symptoms in contrast to imaging findings. The predominant symptom is dyspnoea followed by cough and occasionally chest pain. Though various hypotheses for the pathogenesis of this disorder have been proposed, it is now believed that a mutation in the type Ib sodium-phosphate cotransporter gene (SLC34A2 gene), that is involved in phosphate homeostasis in various organs including lungs and prevents excessive phosphate accumulation that may later act as a nidus for formation of microliths, is responsible for the pathology.4

The chest radiographs usually show diffuse, bilateral areas of micronodular calcifications, resembling a “sandstorm”, that predominate in the middle and lower zones of lungs.1,2,5 The calcification may be so dense that it may obliterate the heart borders and the diaphragm. A black pleural line is another typical finding that appears as an area of hyperlucency, caused by the water density of pleura, between the calcified lung parenchyma and the ribs.5 The characteristic HRCT chest findings include ground-glass opacities probably due to small calculi in alveoli, subpleural linear calcifications, confluent and diffuse calcified nodules, calcification along bronchovascular bundles and small thin-walled subpleural cysts.5 The inter-lobular septa are of calcium density due to the deposition of calcospherites within the peripheral lobular parenchyma adjacent to the septa.5 Rarely, multiple calcified plaques may be seen along the costal pleura.8

Bone scintigraphy using technetium-99m labelled diphosphonate compounds, that have a natural affinity for calcification foci at soft tissue level, may detect early pulmonary calcification in PAM.7 Some cases may also show a high FDG uptake in both lungs on FDG-PET examination.8 Other investigations include demonstration of microliths in sputum and fluid of bronchoalveolar lavage or on histological examination of lung biopsies.3

The disease may progress with chronic alveolar calcification causing interstitial inflammation and fibrosis leading to decreased lung volumes and eventually right heart failure.9 Currently, the only effective therapy is lung transplantation especially when it is performed before the disease progresses to an advanced stage.3 Disodium etidronate, which acts by inhibiting microcrystal growth of hydroxyapatite, and thus, presenting ectopic calcification, has been used to treat PAM with mixed results. Some reports have shown little or no benefit while a recent study10 has demonstrated an improvement in lung functions and radiological changes.

In our patient, though the FDG-PET examination did not show any significant uptake in the lungs, the characteristic CT and bone scintigraphy findings were
consistent with the diagnosis of PAM. The parenchymal calcification was not extensive enough to give rise to the black pleural line. Since she had no respiratory symptoms and her spirometry showed only a mild restrictive abnormality, a decision was made to keep her under observation with periodic reassessments. She remains stable over a six-month follow-up period.

ACKNOWLEDGEMENTS

The authors would like to thank Dr Bhavin Jankharia, Consultant Radiologist, Piramal Diagnostic Jankharia Imaging, Mumbai, India for the computed tomographic images and Dr Bhairavi Bhat, Radio Isotope Center, T.N. Medical College and B.Y.L. Nair Hospital, Mumbai for the bone scintigraphy images.

REFERENCES


4th Asian Pacific Congress on Bronchology and Interventional Pulmonology

Jointly with

17th Annual Conference of Indian Association for Bronchology (IAB)

from

January 19-22, 2012

at

Jaipur [Rajasthan], India

For further information and details, please contact: Dr S.K. Sarkar, Organising President, 4th APCB 2012, C-24, Vaishali Marg, Vaishali Nagar, Jaipur - 302 021[Rajasthan]; Phone: 91-141-2357660; Fax: 91-141-2355660; E-mail: info@apcb2012.com; Website: www.apcb2012.com
Full text articles published in IJCDAS from July-September 2003 onwards can be accessed online on Internet through the following sites

V.P. Chest Institute’s site: http://www.vpci.org.in
Indmed’s site: http://medind.nic.in

Guidance for Authors appears in every issue.

Authors’ Index appears in the last issue of the year

---

Clinical Trials Registry-India

A Clinical Trials Registry-India has been set up jointly by the Department of Science and Technology (DST), World Health Organisation (WHO) and Indian Council of Medical Research at the National Institute of Medical Statistics (NIMS), New Delhi. This Registry will provide a platform for registration of all clinical trials. The objective of the Registry is to establish a public record system by registering all prospective clinical trials of any intervention (drug, surgical procedure, preventive measures, lifestyle modifications, devices, educational or behavioural treatment, rehabilitation strategies and complementary therapies) conducted in India involving human participants. The Registry will be made publicly available on the internet at no cost. The website of the Indian Registry is www.ctri.in.